{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:21Z","timestamp":1790790201394,"version":"4.1.0"},"reference-count":22,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2023,7,29]]},"DOI":"10.1536\/ihj.23-075","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T22:15:43Z","timestamp":1689286543000},"page":"647-653","source":"Crossref","is-referenced-by-count":9,"title":["Changes in Exercise Tolerance over Time in Patients with Transthyretin Amyloidosis Cardiomyopathy Treated with Tafamidis"],"prefix":"10.1536","volume":"64","author":[{"given":"Yuta","family":"Nakaya","sequence":"first","affiliation":[{"name":"Department of Rehabilitation, Uwajima City Hospital"},{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Ogimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Uwajima City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kitaoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","first-page":"e178","volume":"126","year":"2012","unstructured":"1. Quarta CC, Kruger JL, Falk RH. Cardiac amyloidosis. Circulation 2012; 126: e178-82.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, <i>et al<\/i>. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585-94.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gilstrap LG, Dominici F, Wang Y, <i>et al<\/i>. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 2019; 12: e005407.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012; 1: e000364.","DOI":"10.1161\/JAHA.111.000364"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail 2019; 6: 1128-39.","DOI":"10.1002\/ehf2.12518"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Maurer MS, Schwartz JH, Gundapaneni B, <i>et al<\/i>. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007-16.","DOI":"10.1056\/NEJMoa1805689"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kitaoka H, Izumi C, Izumiya Y, <i>et al<\/i>. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 2020; 84: 1610-71.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rockwood K, Theou O. Using the clinical frailty scale in allocating scarce health care resources. Can Geriatr J 2020; 23: 210-5.","DOI":"10.5770\/cgj.23.463"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Connors LH, Sam F, Skinner M, <i>et al<\/i>. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 2016; 133: 282-90.","DOI":"10.1161\/CIRCULATIONAHA.115.018852"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nicol M, Deney A, Lairez O, <i>et al<\/i>. Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. Eur J Heart Fail 2021; 23: 231-9.","DOI":"10.1002\/ejhf.2016"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fleg JL, Cooper LS, Borlaug BA, <i>et al<\/i>. Exercise training as therapy for heart failure: current status and future directions. Circ Heart Fail 2015; 8: 209-20.","DOI":"10.1161\/CIRCHEARTFAILURE.113.001420"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies. Circ J 2013; 77: 293-300.","DOI":"10.1253\/circj.CJ-12-1235"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. McGavock JM, Hastings JL, Snell PG, <i>et al<\/i>. A forty-year follow-up of the Dallas Bed Rest and Training study: the effect of age on the cardiovascular response to exercise in men. J Gerontol A Biol Sci Med Sci 2009; 64: 293-9.","DOI":"10.1093\/gerona\/gln025"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Maurer MS, King DL, El-Khoury Rumbarger L, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail 2005; 11: 177-87.","DOI":"10.1016\/j.cardfail.2004.10.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010; 3: 588-95.","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rapezzi C, Milandri A, Lorenzini M. The complex interplay between systolic and diastolic function at rest and during exercise in heart failure: the case of cardiac amyloidosis. Eur J Heart Fail 2017; 19: 1466-7.","DOI":"10.1002\/ejhf.968"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Badr Eslam R, \u00d6zt\u00fcrk B, Rettl R, <i>et al<\/i>. Impact of tafamidis and optimal background treatment on physical performance in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 2022; 15: e008381.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008381"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ijaz N, Buta B, Xue QL, <i>et al<\/i>. Interventions for frailty among older adults with cardiovascular disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2022; 79: 482-503.","DOI":"10.1016\/j.jacc.2021.11.029"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ochi Y, Kubo T, Baba Y, <i>et al<\/i>. Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. Circ J 2022; 86: 1121-8.","DOI":"10.1253\/circj.CJ-21-0965"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bozkurt B, Fonarow GC, Goldberg LR, <i>et al<\/i>. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol 2021; 77: 1454-69.","DOI":"10.1016\/j.jacc.2021.01.030"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Guazzi M. Assessment for exercise prescription in heart failure. Card Fail Rev 2015; 1: 46-9.","DOI":"10.15420\/CFR.2015.01.01.46"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bernabei R, Landi F, Calvani R, <i>et al<\/i>. Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ 2022; 377: e068788.","DOI":"10.1136\/bmj-2021-068788"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/4\/64_23-075\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:48:25Z","timestamp":1715575705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/4\/64_23-075\/_article"}},"subtitle":["A Preliminary Study"],"short-title":[],"issued":{"date-parts":[[2023,7,29]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.23-075","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,29]]},"article-number":"23-075"}}